Water in nigella oil microemulsion for enhanced oral bioavailability of linagliptin.
Class III drugs
Hypoglycemic effect
Linagliptin
Microemulsion
Nigella oil
Oral absorption
Journal
Drug delivery and translational research
ISSN: 2190-3948
Titre abrégé: Drug Deliv Transl Res
Pays: United States
ID NLM: 101540061
Informations de publication
Date de publication:
13 May 2024
13 May 2024
Historique:
accepted:
23
04
2024
medline:
14
5
2024
pubmed:
14
5
2024
entrez:
13
5
2024
Statut:
aheadofprint
Résumé
Linagliptin is hydrophilic antidiabetic with poor oral bioavailability due to poor permeability and pre-systemic metabolism. The objective was to assess w/o microemulsion for enhanced oral bioavailability of linagliptin. Nigella oil was used as oily phase based on its reported antidiabetic effect. Isopropyl myristate (IPM) or capryol were combined with nigella oil to impart intestinal membrane permeabilizing abilities. Pseudoternary phase diagrams were constructed utilizing nigella oil in presence and absence of isopropyl myristate or capryol as oily phase using Tween 60 as surfactant. W/O microemulsion formulations were selected from the constructed phase diagrams and linagliptin was loaded in the internal aqueous phase at a concentration of 0.5 mg/ml. The prepared formulations were physically evaluated and linagliptin in vitro release was monitored. Eventually, the in vivo hypoglycemic effect was assessed using diabetic rats. The developed microemulsions were of w/o type and exhibited Newtonian flow behavior with nigella/capryol microemulsion recording the lowest viscosity. The recorded droplet size values were 104.9, 121.2 and 86.4 nm for nigella, nigella/IPM and nigella/capryol microemulsions, respectively. All microemulsion formulations showed slower drug release rate compared with aqueous suspension with nigella/capryol microemulsion showing the highest release rate compared to other microemulsions. Release data from microemulsion best fitted to Higuchi model. In vivo oral hypoglycemic activity measurement reflected a more intensified hypoglycemic effect with rapid onset after oral ingestion of microemulsion compared to linagliptin dispersion. Nigella oil/IPM-based microemulsion was ranked as the most effective. The investigation highlighted the feasibility of w/o microemulsion for enhanced oral bioavailability of hydrophilic drugs like linagliptin.
Identifiants
pubmed: 38740693
doi: 10.1007/s13346-024-01613-x
pii: 10.1007/s13346-024-01613-x
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s).
Références
Gomis R, Espadero RM, Jones R, Woerle HJ, Dugi KA. Efficacy and safety of initial combination therapy with linagliptin and pioglitazone in patients with inadequately controlled type 2 diabetes: a randomized, double-blind, placebo-controlled study. Diabetes Obes Metab. 2011. https://doi.org/10.1111/j.1463-1326.2011.01391.x .
doi: 10.1111/j.1463-1326.2011.01391.x
pubmed: 21410628
Barnett AH, Patel S, Harper R, Toorawa R, Thiemann S, von Eynatten M, Woerle HJ. Linagliptin monotherapy in type 2 diabetes patients for whom metformin is inappropriate: an 18-week randomized, double-blind, placebo-controlled phase III trial with a 34- week active-controlled extension. Diabetes Obes Metab. 2012. https://doi.org/10.1111/dom.12011 .
Shah P, Chavda K, Vyas B, Patel S. Formulation development of linagliptin solid lipid nanoparticles for oral bioavailability enhancement: role of P-gp inhibition. Drug Deliv Transl Res. 2021. https://doi.org/10.1007/s13346-020-00839-9 .
doi: 10.1007/s13346-020-00839-9
pubmed: 34609731
Hüttner S, Graefe-Mody EU, Withopf B, Ring A, Dugi KA. Safety, tolerability, pharmacokinetics, and pharmacodynamics of single oral doses of Bi 1356, an inhibitor of dipeptidyl peptidase 4, in healthy male volunteers. J Clin Pharmacol. 2008. https://doi.org/10.1177/0091270008323753 .
doi: 10.1177/0091270008323753
pubmed: 18812608
Heise T, Graefe-Mody EU, Hüttner S, Ring A, Trommeshauser D, Dugi KA. Pharmacokinetics, pharmacodynamics and tolerability of multiple oral doses of linagliptin, a dipeptidyl peptidase-4 inhibitor in male type 2 diabetes patients. Diabetes Obes Metab. 2009. https://doi.org/10.1111/j.1463-1326.2009.01046.x .
doi: 10.1111/j.1463-1326.2009.01046.x
pubmed: 19476477
Fuchs H, Runge F, Held HD, Held. Excretion of the dipeptidyl peptidase-4 inhibitor linagliptin in rats is primarily by biliary excretion and P-gp-mediated efflux. Eur J Pharm Sci. 2012. https://doi.org/10.1016/j.ejps.2011.11.018 .
doi: 10.1016/j.ejps.2011.11.018
pubmed: 22198311
Shaik M, Vanapatla SR. Enhanced oral bioavailability of linagliptin by the influence of gallic acid and ellagic acid in male Wistar albino rats: involvement of p-glycoprotein inhibition. Drug Metab Pers Ther. 2019. https://doi.org/10.1515/dmpt-2018-0020 .
doi: 10.1515/dmpt-2018-0020
pubmed: 31256062
Embaby MA, El Maghraby GM, Osman MA, Sultan AA. Investigation of the effect of concurrently administered carvedilol, atorvastatin and bile salts on intestinal absorption of linagliptin. J Pharm Pharmacol. 2023. https://doi.org/10.1093/jpp/rgad006 .
doi: 10.1093/jpp/rgad006
pubmed: 36856806
Veni DK, Gupta NV. Development and evaluation of Eudragit coated environmental sensitive solid lipid nanoparticles using central composite design module for enhancement of oral bioavailability of linagliptin. Int J Polym Mater Polym Biomater. 2020. https://doi.org/10.1080/00914037.2019.1570513 .
doi: 10.1080/00914037.2019.1570513
Nishu SB, Karmoker JR, Ali FF, Rafa NN, Hoque O, Dewan I. In vitro and ex vivo studies of linagliptin loaded non-ionic surfactant vesicles using statistical optimization. J Adv Med Pharm Sci. 2018. https://doi.org/10.9734/JAMPS/2018/44198 .
Ghosh PK, Majithiya RJ, Umrethia ML, Murthy RS. Design and development of microemulsion drug delivery system of acyclovir for improvement of oral bioavailability. AAPS Pharm Sci Tech. 2006. https://doi.org/10.1208/pt070377 .
doi: 10.1208/pt070377
Gundogdu E, Alvarez IG, Karasulu E. Improvement of effect of water-in-oil microemulsion as an oral delivery system for fexofenadine: in vitro and in vivo studies. Int J Nanomed. 2011. https://.
Li Y, Song J, Tian N, Cai J, Huang M, Xing Q, Wang Y, Wu C, Hu H. Improving oral bioavailability of metformin hydrochloride using water-in-oil microemulsions and analysis of phase behavior after dilution. Int J Pharm. 2014. https://doi.org/10.1016/j.ijpharm.2014.07.011 .
doi: 10.1016/j.ijpharm.2014.07.011
pubmed: 25545797
pmcid: 4074574
Al-Hader A, Aqel M, Hasan Z. Hypoglycemic effects of the volatile oil of Nigella sativa seeds. Int J Pharmacog. 1993. https://doi.org/10.3109/13880209309082925 .
doi: 10.3109/13880209309082925
Benhaddou-Andaloussi A, Martineau LC, Vallerand D, Haddad Y, Afshar A, Settaf A, Haddad PS. Multiple molecular targets underlie the antidiabetic effect of Nigella sativa seed extract in skeletal muscle, adipocyte and liver cells. Diabetes Obes Metab. 2010. https://doi.org/10.1111/j.1463-1326.2009.01131.x .
doi: 10.1111/j.1463-1326.2009.01131.x
pubmed: 19788435
Mathur ML, Gaur J, Sharma R, Haldiya KR. Antidiabetic properties of a spice plant Nigella sativa. J Endocrinol Metab. 2011. https://doi.org/10.4021/jem12e .
doi: 10.4021/jem12e
Hamdan A, Haji Idrus R, Mokhtar MH. Effects of Nigella sativa on type-2 diabetes mellitus: a systematic review. Int J Environ Res Public Health. 2019. https://doi.org/10.3390/ijerph16244911 .
doi: 10.3390/ijerph16244911
pubmed: 31817324
pmcid: 6950756
Srinivasan K. Cumin (Cuminum cyminum) and black cumin (Nigella sativa) seeds: traditional uses, chemical constituents, and nutraceutical effects. Food Qual Saf. 2018. https://doi.org/10.1093/fqsafe/fyx031 .
doi: 10.1093/fqsafe/fyx031
Eid RK, Arafa MF, Ashour DS, Essa EA, Zoghroban HS, Issa YA, Nomeir HM, Safia HS, El Maghraby GM. Eudragit coated microemulsion for enhanced efficacy of spiramycin against toxoplasmic encephalitis. J Drug Deliv Sci Technol. 2022. https://doi.org/10.1016/j.jddst.2022.103137 .
doi: 10.1016/j.jddst.2022.103137
Wahab AE, Essa LM, El Maghraby EA, Arafa GM. The development and evaluation of phase transition microemulsion for ocular delivery of acetazolamide for glaucoma treatment. AAPS Pharm Sci Tech. 2023. https://doi.org/10.1208/s12249-022-02459-7 .
doi: 10.1208/s12249-022-02459-7
Eid RK, Ashour DS, Essa EA, El Maghraby GM, Arafa MF. Chitosan coated nanostructured lipid carriers for enhanced in vivo efficacy of albendazole against Trichinella Spiralis. Carbohydr Polym. 2020. https://doi.org/10.1016/j.carbpol.2019.115826 .
doi: 10.1016/j.carbpol.2019.115826
pubmed: 31952620
Ramachandran B, Ravi K, Narayanan V, Kandaswamy M, Subramanian S. Protective effect of macrocyclic binuclear oxovanadium complex on oxidative stress in pancreas of streptozotocin induced diabetic rats. Chem Biol Interact. 2004. https://doi.org/10.1016/j.cbi.2004.06.007 .
doi: 10.1016/j.cbi.2004.06.007
pubmed: 15356917
Arafa MF, El-Gizawy SA, Osman MA, El Maghraby GM. Co-crystallization for enhanced dissolution rate of nateglinide: in vitro and in vivo evaluation. J Drug Deliv Sci Technol. 2017. https://doi.org/10.1016/j.jddst.2017.01.005 .
doi: 10.1016/j.jddst.2017.01.005
El Maghraby GM. Self microemulsifying and microemulsion systems for transdermal delivery of indomethacin: effect of phase transition. Colloids Surf B. 2010. https://doi.org/10.1016/j.colsurfb.2009.10.003 . https://.
doi: 10.1016/j.colsurfb.2009.10.003
Kim GG, Poudel BK, Marasini N, Lee DW, Hiep TT, Yang KY, Kim JO, Yong CS, Choi HG. Enhancement of oral bioavailability of fenofibrate by solid self-microemulsifying drug delivery systems. Drug Develop Ind Pharm. 2013. https://doi.org/10.3109/03639045.2012.719903 .
doi: 10.3109/03639045.2012.719903
Kang BK, Chon SK, Kim SH, Jeong SY, Kim MS, Cho SH, Lee HB, Khang G. Controlled release of paclitaxel from microemulsion containing PLGA and evaluation of anti-tumor activity in vitro and in vivo. Int J Pharm. 2004. https://doi.org/10.1016/j.ijpharm.2004.08.008 .
Shah BM, Misra M, Shishoo CJ, Padh H. Nose to brain microemulsion-based drug delivery system of rivastigmine: formulation and ex-vivo characterization. Drug Deliv. 2015. https://.
Zheng D, Lv C, Sun X, Wang J, Zhao Z. Preparation of a supersaturatable self-microemulsion as drug delivery system for ellagic acid and evaluation of its antioxidant activities. J Drug Deliv Sci Technol. 2019. https://doi.org/10.1016/j.jddst.2019.101209 .
doi: 10.1016/j.jddst.2019.101209
Chan J, El Maghraby GM, Craig JP, Alany RG. Phase transition water-in-oil microemulsions as ocular drug delivery systems: in vitro and in vivo evaluation. Int J Pharm. 2007. https://doi.org/10.1016/j.ijpharm.2006.10.004 .
doi: 10.1016/j.ijpharm.2006.10.004
pubmed: 18207676
El Maghraby GM. Transdermal delivery of hydrocortisone from eucalyptus oil microemulsion: effects of cosurfactants. Int J Pharm. 2008. https://doi.org/10.1016/j.ijpharm.2007.12.022 .
doi: 10.1016/j.ijpharm.2007.12.022
pubmed: 18243604
Qushawy M, Soliman GM, Mortagi Y, El-Sherbiny M, Elsherbiny N. Development, optimization, and assessment of losartan nano-bilosomes to mitigate diabetes-induced microvascular complications in Sprague Dawley rats. J Drug Deliv Sci Technol. 2024. https://doi.org/10.1016/j.jddst.2023.105295 .
doi: 10.1016/j.jddst.2023.105295
Eid RK, Arafa MF, Ashour DS, Essa EA, El-Wakil ES, Younis SS, El Maghraby GM. Surfactant vesicles for enhanced antitoxoplasmic effect of norfloxacin: in vitro and in vivo evaluations. Int J Pharm. 2023. https://doi.org/10.1016/j.ijpharm.2023.122912 .
doi: 10.1016/j.ijpharm.2023.122912
pubmed: 37015296
Glavas-Dodov M, Fredro-Kumbaradzi E, Goracinova K, Calis S, Simonoska M, Hincal AA. 5-Fluorouracil in topical liposome gels for anticancer treatment-formulation and evaluation. Acta Pharm. 2003;53:241–50.
pubmed: 14769231
Shazly G, Nawroth T, Langguth P. Comparison of dialysis and dispersion methods for in vitro release determination of drugs from multilamellar liposomes. Dissolution Technol. 2008. https://doi.org/10.14227/DT150208P7 .
doi: 10.14227/DT150208P7
Trotta M. Influence of phase transformation on indomethacin release from microemulsions. J Control Release. 1999. https://doi.org/10.1016/s0168-3659(99)00094-2 .
doi: 10.1016/s0168-3659(99)00094-2
pubmed: 10425344
Sahoo RK, Biswas N, Guha A, Sahoo N, Kuotsu K. Development and in vitro/in vivo evaluation of controlled release provesicles of a nateglinide–maltodextrin complex. Acta Pharm Sin B. 2014. https://doi.org/10.1016/j.apsb.2014.08.001 .
doi: 10.1016/j.apsb.2014.08.001
pubmed: 26579411
pmcid: 4629096
El Maghraby GM, Elsisi AE, Elmeshad GA. Development of liquid oral sustained release formulations of nateglinide: in vitro and in vivo evaluation. J Drug Deliv Sci Technol. 2015. https://doi.org/10.1016/j.jddst.2015.06.011 .
doi: 10.1016/j.jddst.2015.06.011
Nickavar B, Mojab F, Javidnia K, Amoli MA. Chemical composition of the fixed and volatile oils of Nigella sativa L. from Iran. Z für Naturforschung C. 2003. https://doi.org/10.1515/znc-2003-9-1004 .
doi: 10.1515/znc-2003-9-1004
El Maghraby GM, Ahmed AA, Osman MA. Penetration enhancers in proniosomes as a new strategy for enhanced transdermal drug delivery. Saudi Pharm J. 2015. https://doi.org/10.1016/j.jsps.2014.05.001 .
doi: 10.1016/j.jsps.2014.05.001
pubmed: 25685045
Hu L, Yang J, Liu W, Li L. Preparation and evaluation of ibuprofen-loaded microemulsion for improvement of oral bioavailability. Drug Deliv. 2011. https://doi.org/10.3109/10717544.2010.522613 .
doi: 10.3109/10717544.2010.522613
pubmed: 21688973
Tang TT, Hu XB, Liao DH, Liu XY, Xiang DX. Mechanisms of microemulsion enhancing the oral bioavailability of puerarin: comparison between oil-in-water and water-in-oil microemulsions using the single-pass intestinal perfusion method and a chylomicron flow blocking approach. Int J Nanomed. 2013. https://doi.org/10.2147/IJN.S51469 .
doi: 10.2147/IJN.S51469
Xiao Y, Chen X, Yang L, Zhu X, Zou L, Meng F, Ping Q. Preparation and oral bioavailability study of curcuminoid-loaded microemulsion. J Agric Food Chem. 2013. https://doi.org/10.1021/jf400002x .
doi: 10.1021/jf400002x
pubmed: 24308380
pmcid: 3915300
Koli AR, Ranch KM, Patel HP, Parikh RK, Shah DO, Maulvi FA. Oral bioavailability improvement of felodipine using tailored microemulsion: surface science, ex vivo and in vivo studies. Int J Pharm. 2021. https://doi.org/10.1016/j.ijpharm.2021.120202 .
doi: 10.1016/j.ijpharm.2021.120202
pubmed: 33493600
Engelbrecht TN, Demé B, Dobner B, Neubert RH. Study of the influence of the penetration enhancer isopropyl myristate on the nanostructure of stratum corneum lipid model membranes using neutron diffraction and deuterium labelling. Skin Pharmacol Physiol. 2012. https://doi.org/10.1159/000338538 .
doi: 10.1159/000338538
pubmed: 22614257
Buya AB, Terrasi R, Mbinze JK, Muccioli GG, Beloqui A, Memvanga PB, Préat V. Quality-by-design-based development of a voxelotor self-nanoemulsifying drug-delivery system with improved biopharmaceutical attributes. Pharmaceutics. 2021. https://doi.org/10.3390/pharmaceutics13091388 .
doi: 10.3390/pharmaceutics13091388
pubmed: 34959323
pmcid: 8708335
Cao X, Zhu Q, Wang QL, Adu-Frimpong M, Wei CM, Weng W, Bao R, Wang YP, Yu JN, Xu XM. Improvement of oral bioavailability and Anti-tumor Effect of Zingerone Self-Microemulsion Drug Delivery System. J Pharm Sci. 2021. https://doi.org/10.1016/j.xphs.2021.01.037 .
doi: 10.1016/j.xphs.2021.01.037
pubmed: 34742730
Kawakami K, Yoshikawa T, Hayashi T, Nishihara Y, Masuda K. Microemulsion formulation for enhanced absorption of poorly soluble drugs: II. In vivo study. J Control Release. 2002. https://doi.org/10.1016/S0168-3659(02)00050-0 .
doi: 10.1016/S0168-3659(02)00050-0
pubmed: 11992680